Annexon (NASDAQ:ANNX) highlighted progress across three programs targeting the classical complement pathway during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, with President and ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

Creative Biolabs expands its research capabilities, offering diversified tools and services to support global biomedical innovation. SHIRLEY, NY, UNITED STATES, February 27, 2026 /EINPresswire.com/ — ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Supa Nova by Chanté Timothy, a graphic novel about a young Black girl with a love for science, won the children’s fiction category and inaugural children’s choice prize ...

A replay of the webcast will be archived on the Annexon website for 30 days following the presentation. Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to respond well to standard drug .

-- The unmet need and current treatment landscape for GA -- The mechanism of disease and role of C1q -- Vonaprument, Annexon's neuroprotective C1q inhibitor with the potential to be the first targeted ...

1 Scientific Department, Wellcomet GmbH, Karlsruhe, Germany 2 Touchstone Diabetes Center, University of Texas Southwestern Medical Center, Dallas, TX, United States Hypertrophic scars (HTS) and ...

Expert Rev Clin Immunol. 2008;4(3):379-390. Since there are no genetic deficiencies of CRP in man, animal models have been used to study the role of CRP in inflammatory disease. Two methods have been ...